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Edited by S. RadfordAbstractThe formation of amyloid β (Aβ) fibrils is crucial in initiating the cascade of pathological events that culminates
in Alzheimer's disease. In this study, we investigated the mechanism of Aβ fibril formation from
hydrodynamically well defined species under controlled aggregation conditions. We present a detailed
mechanistic model that furnishes a novel insight into the process of Aβ42 fibril formation and the molecular
basis for the different structural transitions in the amyloid pathway. Our data reveal the structure and
polymorphism of Aβ fibrils to be critically influenced by the oligomeric state of the starting materials, the ratio of
monomeric-to-aggregated forms of Aβ42 (oligomers and protofibrils), and the occurrence of secondary
nucleation. We demonstrate that monomeric Aβ42 plays an important role in mediating structural transitions in
the amyloid pathway, and for the first time, we provide evidences that Aβ42 fibrillization occurs via a combined
mechanism of nucleated polymerization and secondary nucleation. These findings will have significant
implications to our understanding of the molecular basis of amyloid formation in vivo, of the heterogeneity of
Aβ pathology (e.g., diffuse versus amyloid plaques), and of the structural basis of Aβ toxicity.
© 2013 Elsevier Ltd. All rights reserved.Introduction
Plaques resulting from the aggregation and
accumulation of fibrillar amyloid β (Aβ) peptides in
the brain are a hallmark of Alzheimer's disease.1,2
Aβ peptides evolve from the sequential cleavage
of amyloid precursor proteins by β- and γ-
secretases.3,4 The predominant peptide forms are
Aβ40 and Aβ42. Although the levels of Aβ40
peptides are significantly higher than those of
Aβ42, the latter form is more toxic, has a much
higher propensity to aggregate, and is believed to be
crucial in initiating amyloid formation and the
pathogenesis of Alzheimer's disease.5 The insoluble
plaques that are formed in patients with Alzheimer's
disease are composed of Aβ fibrils. An increase in
the production of Aβ peptides and/or fibril formation0022-2836/$ - see front matter © 2013 Elsevier Ltd. All rights reservecould accelerate the onset of the disease. Hence,
therapeutic strategies focus on lowering the levels of
Aβ peptides and/or inhibiting their aggregation.
In vitro, synthetic and recombinant forms of Aβ
peptides undergo structural changes leading to the
formation of oligomeric intermediates and amyloid
fibrils that resemble those isolated from the brains of
patients with Alzheimer's disease.6–8 Biophysical
studies relating to the aggregation of Aβ peptides
and to fibrillogenesis have improved our understand-
ing of the mechanism underlying amyloid formation
in vivo and have formed the basis for the hypothesis
that this process is implicated in the pathogenesis of
Alzheimer's disease. Amyloid formation comprises a
highly ordered process of nucleated polymerization,
which is characterized by a slow nucleation phase
during which Aβ monomers aggregated to formd. J. Mol. Biol. (2013) 425, 1765–1781
1766 Molecular Basis of Amyloid Polymorphismoligomeric nuclei, and a rapid growth phase involv-
ing the addition of monomers, the formation of fibrils,
and their growth.9,10 Previous studies involving
in situ atomic force microscopy (AFM) or transmis-
sion electron microscopy (TEM) have revealed Aβ42
fibrillogenesis to proceed via the formation of high-
molecular-weight protofibrils.11,12 The kinetics of
protofibril formation and stability and the structure
of the final fibrils depend greatly upon ambient
conditions such as pH, temperature, buffer compo-
sition, and peptide concentration,13–20 as well as
upon the hydrophobicity or hydrophilicity of the
substrate.21 Although the mechanism underlying
the aggregation of Aβ peptides in vitro has been the
subject of numerous investigations over the past
two decades, many fundamental questions remain
unanswered. For example, (1) what triggers the
aggregation of Aβ peptides? (2) What is the
relationship between the different oligomeric inter-
mediates in the amyloid pathway? (3) What are the
molecular and structural factors that determine the
final structure and morphology of the Aβ fibrils? To
address these and other issues, we carried out a
series of AFM studies—which included real-time
measurements—to define the mechanisms underly-
ing oligomerization, the formation of protofibrils, and
the formation, association, and growth of fibrils under
controlled conditions using Aβ species of well-
defined size and morphology. Motivated by initial
data from our laboratory—which have suggested the
existence of secondary-nucleation sites on the
surfaces of preformed Aβ42 fibrils—we extended
our studies to determine the structural basis of
secondary nucleation and its role in determining the
final structure and morphology of Aβ fibrils.
Our findings afford a novel insight into the
mechanism of Aβ42 fibril formation and growth, as
well as into themolecular basis of polymorphism, and
for the first time, we provide evidences for the
existence of secondary-nucleation sites on the
surfaces of Aβ42 fibrils. Furthermore, these second-
ary-nucleation sites are not a generic property of
amyloid fibrils per se but specific to the type-2 variety.
In addition, we demonstrate that the concentration of
Aβ42 monomers at different stages of the amyloid
pathway is crucial in determining the structural
properties and heterogeneity of the fibrils formed.Results
Amyloid formation frommonomericAβ42 (Aβ42-M)
To elucidate the mechanism of amyloid formation
from Aβ42, we employed AFM to monitor the
aggregation kinetics, as well as to characterize the
structural properties and the heterogeneity of the
oligomers and fibrils formed from pure preparationsof monomeric Aβ42 (Aβ42-M). After an incubation
period of 30 min at 37 °C, spherical oligomers
(1.00±0.30 nm in diameter) and short protofibrils
(arrows in Fig. 1a) were detected, which is consistent
with previous observations.22 Within 24 h, most of
the spherical oligomers had disappeared and been
replaced by short, flexible chain-like protofibrils
(Fig. 1b), with an average cross-sectional diameter
of 3.95±0.64 nm and an average length of 115.42±
25.84 nm. This finding is likewise consistent with
previous observations.23 Within the protofibrils, the
spacing between the individual spherical oligomers,
which are 3–4 nm in height, ranged between 10 and
25 nm. The height of these oligomers is identical with
that of the spherical oligomers that form at 24 h prior
or coincident with protofibril formation, suggesting
that these beaded chain-like oligomer via linear
growth without changing their height. Some of
protofibrils were straight (arrows in Fig. 1b) and
appeared preferentially to form fibrils with a period-
icity of either 40.48±8.83 nm or 26.47±5.69 nm
(Fig. 1b, inset). After an incubation period of 48 h, the
spherical oligomers and the chain-like protofibrils had
disappeared and been replaced by two types of Aβ
fibrils: type-1 with a periodicity of 27.23±4.25 nm
and a cross-sectional diameter of 4.60±0.56 nm and
type-2 with a periodicity of 40.52±4.96 nm and a
cross-sectional diameter of 4.07±0.46 nm (Fig. 1c).
Protofibrils were occasionally observed on the
surfaces of type-1 and type-2 fibrils (circles in
Fig. 1c), pointing to the possible existence of
secondary-nucleation sites. Type-2 fibrils were
more abundant than type-1 fibrils and exhibited a
much higher frequency of secondary-nucleation
sites. To assess the frequency and specificity of
secondary nucleation, we quantified the number of
secondary nucleation and type-2 fibrils in multiple
images of the sample shown in Fig. 1 and Fig. S1a.
Figure 1f shows the different types of fibrils and the
number of secondary-nucleation events observed for
each fibril. For example, the total number of type-2
fibrils measured by AFM was 305 and the total
number of secondary-nucleation events on type-2
fibrils was 105, whereas only 5 secondary-nucleation
events were observed in type-1 fibrils (n=35;
Fig. 1g). The number of secondary-nucleation events
on the surface of type-2 fibrils decreased after 48 h of
incubation and new types of fibrils (type-3 and wider
fibrils) appeared after 48 h incubation, consistent
with secondary nucleation being a secondary event.
It could be possible that different types and sizes of
fibrils have different affinities to the substrate. These
are not exact quantitative observations of secondary-
nucleation events. However, as seen in Fig. 1f, it
provides an insight of the progression toward new
types of fibrils. Figure S1a illustrates the high
occurrence of type-2 specific secondary nucleation
under these conditions. After an incubation period of
68 h, the protofibrils sprouting from the surfaces of
Fig. 1. Amyloid formation from monomeric Aβ42 (Aβ42-M). Incubation periods of (a) 30 min, (b) 24 h, (c) 48 h, (d) 68 h,
and (e) 68 h. (f) The number of observations counts on secondary nucleation on type-2, branching, type-3, and wider fibrils
at 24 h, 48 h, 72 h, and 96 h of incubation time. (g) Secondary-nucleation site counts on type-1 and type-2 fibrils. (h) Model
of fibrillogenesis from Aβ42-M. Scale bars represent 250 nm. The Z scale represents 25 nm.
1767Molecular Basis of Amyloid Polymorphismtype-2 fibrils had evolved into fibrils, which exhibited
the morphological characteristics and dimensions of
the parent structure (Fig. 1d and Fig. S1b). In
addition, a third type of fibril was observed. The
periodicity of this type-3 fibril (42.78±0.76 nm) was
similar to that of the type-2 fibril, but its cross-
sectional diameter (7.54±1.00 nm) was twice as
great (Fig. 1e). However, wider fibrils (cross-sectional
diameter: 4–5 nm), with a smooth surface contour(Fig. 1e), were frequently observed in conjunction
mainly with type-2 fibrils. Figures S2a and S3 provide
a quantitative summary of the height and periodicity
property of each species measured by AFM during
amyloid formation from Aβ42-M.
On the basis of repeated measurements, we
propose the following model for fibril formation from
Aβ42-M (Fig. 1h). Spherical oligomers appear to be
the primary building blocks for the aggregation of
1768 Molecular Basis of Amyloid PolymorphismAβ42-M. Within 24 h, these give rise to short-beaded
chains of protofibrils via a process of linear elonga-
tion. The protofibrils then undergo self-assemblage
to form type-1 and type-2 fibrils. The type-1 fibrils
were characterized by the same cross-sectional
diameter (~4 nm) and periodicity (~25 nm) as the
protofibrils. This finding suggests that type-1 fibrils
are formed exclusively by a process of which
involves the sequential addition of monomers to
form straight, rod-like structures without any change
in cross-sectional diameter. Interestingly, the pre-
dominating type-2 fibrils have the same cross-
sectional diameter as the type-1 fibrils but a different
periodicity ~40 nm. The detection of each fibril type
at early timepoints—when protofibrils of similar
dimensions dominate (Fig. 1b)—suggests that
type-1 and type-2 fibrils reflect two distinct mecha-
nisms of protofibril association. Type-2 fibrils can
evolve into type-3 and wider fibrils via a combined
mechanism of secondary nucleation and lateral
association. As shown in Fig. 1g, the AFM observa-
tions suggest that the surface of type-2 fibrils is the
most probable secondary-nucleation sites. It is
conceivable that Aβ42-M favors binding to type-2
fibrils. However, we note here that we cannot rule out
an assembly pathway where spherical oligomers
form independently and then stick to preformed
fibrils either in solution during incubation or in AFM
sample preparation. The disappearance of branch-
ing type-2 fibrils and the emergence of type-3 fibrils
suggest that the latter are formed by the stacking of
two type-2 fibrils. However, wider fibrils appeared to
sprout from the surfaces of type-2 fibrils.
Secondary-nucleation events confirmed by the
kinetic analysis with ThT assay
A sigmoid function as a function of time with
thioflavin T (ThT) signal always implies the genera-
tion of new aggregates during the aggregation by the
secondary pathways (fibril fragmentation or surface-
catalyzed nucleation).24,25 As reported by other
studies,24–32 a reaction dominated by secondary
nucleation undergoes an exponential increase in the
early stages, as a result of the positive feedback.
The positive feedback is a consequence of the fact
that formed aggregates accelerate the rate of
production of further aggregates.24
In order to support our morphological evidence of
secondary-nucleation events on the surface of
preexisting fibrils, we monitored the ThT fluores-
cence assay of Aβ42-M over time at three different
protein concentrations. Figure 2a shows the aggre-
gation reaction monitored by ThT fluorescence data
of Aβ42-M at the different concentrations, exhibiting
sigmoid form as a function of time with a distinct lag
phase at low concentrations (10 μM and 20 μM). At
high concentration (40 μM), the lag phase was
shortened with increasing protein concentration.The continuous lines in Fig. 2awas fitted according to
S ¼ S∞
1þ e− t−t50ð Þ=sð Þ ð1Þ
where S∞ is the amplitude of signal change, t is the
time, t50 is the time at which the change in signal is at
50%, and s is a time constant.25 The lag time (tD) was
calculated using the formula tD= t50−2s as described
in Nielsen et al.30 Note that Eq. (1) is an empirical
sigmoid fit function, and thus, the constants do not
have an interpretation in terms of rates of molecular
processes. Our data with increasing initial protein
concentration (Fig. 2a) were well fitted by the sigmoid
growth corresponding to Eq. (1). For the clear
justification of secondary pathway, the initial 50% of
the signal intensity with concentrations 10 μM and
20 μM was fitted to an exponential time function
(continuous line in Fig. 2b and c) and a quadratic
function (broken line in Fig. 2b and c). It was reported
by others24,25 that the primary nucleation pathway is
following the quadratic in time, ~ t2, while the reaction
dominated by secondary nucleation pathway un-
dergoes an exponential increase in the early stages
of the reaction.24 The initial parts of our data with a
20 μM concentration, which was used for Aβ42
fibrillogenesis study, were fitted well by an exponen-
tial time function but poorly fitted by the t2 function.
This implies that the Aβ42 aggregation is not
dominated by the primary pathway and that our
kinetic data provide evidences of secondary nucle-
ation pathways. In contrast, the data at 10 μM
concentration were well fitted to an exponential time
function but did not show a significant difference with
the t2 function.
In addition, Fig. 2d shows the plot of experimental
estimated t50 (half-time) values of the ThT fluores-
cence-monitored kinetics against protein concentra-
tion. The straight line was fitted with a linear
relationship when plotted as a log–log plot using
Eq. (2).
log tf ∝− 1þ n2 log c0 ð2Þ
where tf is the time at which a given fractional extent
(f) of aggregation is reached and c0 is the total
protein concentration.24 Since Fig. 2a–c shows the
reaction dominated by secondary pathway, we could
use the slope, − 1þn2 , from Fig. 2d using Eq. (2) in
order to determine the reaction order.24 The slope in
Fig. 2d was −1.424 yielding an n value, reaction
order of the nucleation process, of 1.848.24 If n=0, it
corresponds to a monomer-independent secondary
pathway (filament fragmentation), whereas if nN0, it
corresponds to a monomer-dependent process that
implies a surface-catalyzed nucleation, creating
the new aggregates at a rate that depends on
the monomeric concentration and the existing
aggregates.24 The positive value of n from our result
Fig. 2. Kinetics of amyloid fibril formation of an Aβ42-M sample at the concentrations of 10 μM, 20 μM, and 40 μM. (a)
The ThT fluorescence data for increasing initial monomer concentration. The continuous line through the data points were
fitted to Eq. (1). The initial 50% of the ThT fluorescence data of aggregation (b) 10 μM and (c) 20 μM were fitted to an
exponential time function (continuous line) and a quadratic time function (broken line). (d) A plot of half-time values of ThT
fluorescence against the initial monomer concentration. The continuous line through data points were fitted to Eq. (2).
Slope: −1.424±0.15.
1769Molecular Basis of Amyloid Polymorphismstrongly supports that the secondary-nucleation
events occurred on the surface of preexisting fibrils
not just by fibril–fibril interaction.
Amyloid formation from Aβ42 protofibrils
(Aβ42-PF)
In the absence of excess Aβ42-M, purified Aβ42
protofibrils (Aβ42-PF) do not aggregate into fibrils;
they exist predominantly as curvilinear species
(Fig. 3a), which grow with time but do not
transform into mature ThT-positive amyloid fibrils
(Fig. S4).33,34 Upon the addition of Aβ42-M, the
protofibrils undergo a rapid transition into amyloid
fibrils. Hence, to investigate the transition from
protofibrils to fibrils, we reintroduced Aβ42-M into
solutions containing purified Aβ42-PF and examined
the structural transitions and morphologies of the
resulting fibrillar structures (Fig. 3b–e). When Aβ42-
M and Aβ42-PF were mixed, the ThT-binding value
increased with time (Fig. S4). The morphology of the
fibrillar structures depended upon the M/PF ratio. At
higher M/PF ratios (5/1), the fibrils observed after87 h resembled those formed during the fibrillogen-
esis from Aβ42-M (Fig. S5), whereas at lower M/PF
ratios (0.3/1), long protofilaments (arrows in Fig. 3b)
and numerous protofibrils predominated (Fig. 3b).
The individual protofilaments appeared to have a
periodic “twist” at intervals of ~100 nm. Whether this
“twist” reflects the arrangement of the β-sheets in the
protofilaments is unclear. The average cross-
sectional diameter of the protofilaments (2.53±
0.72 nm) is consistent with previous observations.35
Mixed fibrillar structures consisting of protofilaments
and type-4 fibrils defined below were observed in the
same sample, thereby indicating the existence of a
direct relationship between the two structures (oval
in Fig. 3b), as reported by Adamcik et al.36 After an
incubation period of 72 h, most of protofibrils had
disappeared and been replaced by protofilaments
(Fig. 3c). However, at this 72-h juncture, the average
cross-sectional diameter of the protofilaments
(3.79±0.70 nm) exceeded that observed at 48 h
(arrows in Fig. 3c). After 216 h, most of protofila-
ments had disappeared and been replaced by type-4
fibrils, which exhibited a regular periodicity of 74.66±
Fig. 3. Amyloid formation from Aβ42 protofibrils (Aβ42-PF). (a) Purified Aβ42-PF after 64 h of incubation. A mixture of
Aβ42-M and Aβ42-PF after (b) 48 h, (c) 72 h, (d) 216 h, and (e) 578 h. (f) Model of fibrillogenesis from a mixture of Aβ42-M
and Aβ42-PF. Scale bars represent 500 nm (a–e) and 100 nm (inset). The Z scale represents 25 nm.
1770 Molecular Basis of Amyloid Polymorphism8.90 nm and a cross-sectional diameter of 7.29±
0.82 nm (Fig. 3d). After an incubation period of
578 h, we observed a small population of type-5
fibrils, which were formed by the association of three
protofilaments (Fig. 3e). However, at this juncture,
and even after longer incubation times, type-4 fibrils
predominated. Figure 3e affords evidence by AFM of
an intermediate stage of assemblage, involving the
intertwining of two protofilaments to form a type-4
fibril and of three protofilaments to form a type-5 fibril
(see Fig. S6). These structures (protofilaments and
mixed fibrils) were observed only during amyloid
formation from samples containing a mixture of
Aβ42-M and Aβ42-PF. We provided the table and
histogram of height and periodicity property with the
morphology of each species measured by AFM
during amyloid formation from the mixture of Aβ42-M
and PF. (Figs. S2b and S3).On the basis of these observations, we propose a
model of fibrillogenesis (Fig. 3f) in which the addition
of monomers to protofibrils leads to the formation of
protofilaments; the protofilaments self-associate and
intertwine to form mature type-4 fibrils and, occa-
sionally, after longer incubation times, type-5 fibrils.
Interestingly, these protofilaments were not ob-
served during fibrillogenesis from Aβ42-M. Type-4
fibrils are highly twisted, and the twists occur at
regular (periodic) intervals. Along the longitudinal
axis of type-4 fibrils, a difference in cross-sectional
diameter of 3.47±0.76 nm is observed between the
maxima and the minima,36 which corresponds to the
cross-sectional diameter of a protofilament (3.79±
0.70 nm). Consistent with previous observations,35
the mature fibril is composed of two protofilaments.
Taken together, these findings support our previous
contention that the ratio of monomers to protofibrils is
1771Molecular Basis of Amyloid Polymorphisma crucial determinant of Aβ aggregation and
toxicity.33,34
Other evidences for secondary-nucleation sites
Our former studies on fibrillogenesis from Aβ42-M
pointed to the existence of secondary-nucleation
sites on the surfaces of amyloid fibrils. To confirm
these findings and to ascertain whether secondary
nucleation depends upon the structure and the
morphology of the fibrils, we added Aβ42-M to
samples containing either preformed type-2 fibrils
or protofilaments, which were then incubated for a
further 72 h or 47 h, respectively.
The reintroduction of Aβ42-M into a solution
containing preformed type-2 fibrils (Fig. 4) led to
further growth at the secondary-nucleation sites and
accelerated the process of fibrillogenesis; it also led
to the emergence of type-3 (asterisk in Fig. 4) and
wider (arrows in Fig. 4) fibrils, which arose by the
lateral association of type-2 fibrils. No secondary-
nucleation events were observed on the surfaces of
either the type-3 or the wider fibrils.
The reintroduction of Aβ42-M into a solution
containing protofilaments led, after 24 h, to the
formation predominantly of thicker protofilaments
(Fig. 5a), upon the surfaces of which no signs of
secondary nucleation were detected on the surfaces
of protofilaments. These findings support earlier
observations indicating that only mature type-2 fibrils
are capable of secondary nucleation fibrillogenesis
on their surfaces.
After 23 h, we observed a transition from proto-
filaments to mixed fibrillar structures, which included
type-1, type-4, and type-5, with type-4 predominating
(Fig. 5b). The type-4 and the type-5 fibrils observed
under these conditions exhibited the same morpho-
logical features as those in samples containing a
mixture of monomers and protofibrils (Fig. 3d and e).
Based on these observations, we propose the
following model of fibrillogenesis under conditions in
which Aβ42-M and Aβ42-PF co-exist. Type-4 fibrilsrepresent 500 nm and 90 nm (inset). The Z scale represents
procedure and the results.predominate under these conditions. Given the
periodic difference in the cross-sectional diameter
of type-4 fibrils (3.50±0.54 nm) and the morpholog-
ical features of the transition stage (Fig. S6a), the
former appear to be formed by the intertwining of two
thicker protofilaments. Type-5 fibrils exhibit a peri-
odicity of 90–150 nm along the longitudinal axis and
have a cross-sectional diameter of 9.17±0.89 nm.
The latter measurement is consistent with their being
composed of three thicker protofilaments. This
conclusion is supported by the repeated observation
of structures manifesting the merger of three thicker
protofilaments to form a type-5 fibril (Fig. S6b). The
type-1 fibrils revealed under these conditions exhib-
ited the same morphological features as those
observed during fibrillogenesis from Aβ42-M
(Figs. 1c and 5c). Conceivably, the reintroduction
of Aβ42-M led to a linear alignment of the peptides to
form beaded chains with the periodicity of type-1
fibrils (30.25±4.86 nm). Accordingly, the population
of type-1 fibrils increased after the reintroduction of
Aβ42-M only during the course, not prior to the
onset, of aggregation. Taken together, these find-
ings demonstrate that the surfaces of fibrils can
serve as templates for the replication of the parent
structure.
Real-time monitoring of the structural transition
from oligomers to protofibrils
Our findings indicate that Aβ42-M plays a crucial
role in determining the pathway of Aβ42 aggregation
and the morphology of the final fibrils. To test this
hypothesis, we investigated the structural transition
from oligomers to protofibrils by in situ AFM. Aβ42
oligomers that had been generated from Aβ42-M
after an incubation period of 4 h were first deposited
upon 3-aminopropyl triethoxysilane (APTES)-modi-
fied mica (Figs. 6a, 7a, and 8a). These samples were
rich in spherical structures, with an average diameter
of 2.2–2.4 nm (Figs. 6a-1, 7a-1, and 8a-2) and in
short assemblies with a similar cross-sectionalFig. 4. (a) AFM image of amyloid
formation from Aβ42-M, 72 h after
reintroducing Aβ42-M into the solu-
tion containing preformed type-2
fibrils (48-h-incubation sample).
This measure led to further growth
and fibrillogenesis at the second-
ary-nucleation sites, to an acceler-
ation of the latter process, and to the
emergence of type-3 (asterisk) and
wider (arrows) fibrils. Scale bars
25 nm. (b) Schematic representation of the experimental
Fig. 5. (a) AFM image of amyloid
formation from a mixture of Aβ42-M
and Aβ42-PF, 24 h after reintrodu-
cing Aβ42-M into the solution con-
taining mainly protofilaments (75-h-
incubation sample). At this juncture,
predominantly thicker protofila-
ments were observed. (b) After an
additional 23 h, type-1, type-4, and
type-5 fibrils were detected, with the
type-4 variety predominating. (c)
The morphological features of the
type-1 fibrils that were ascertained
(left). Fibrils combining the proper-
ties of type-1 and type-5 were
observed (right), but no evidence
of secondary nucleation was
detected. Scale bars represent
500 nm (a and b) and 90 nm (c).
The Z scale represents 25 nm. (d)
Schematic representation of the
experimental procedure and the
results.
1772 Molecular Basis of Amyloid Polymorphismdiameter and a length of ~20 nm.We then examined
the dynamic (real-time) growth of specific oligomers
after the injection of either freshly prepared Aβ42-M
(Fig. 6), oligomers (Fig. 7), or Aβ42-PF (Fig. 8) into
the fluid cell. Our data revealed the rate of oligomer
growth to be most rapid after the introduction of
Aβ42-M (9.9±2.64 nm/min), somewhat slower after
the injection of Aβ42-PF (1.44±0.34 nm/min), and
slowest after the addition of oligomeric Aβ42 (0.75±
0.25 nm/min). Forty minutes after the injection of
Aβ42-M, the oligomers underwent a smooth trans-
formation into elongated structures with a cross-
sectional diameter (~2 nm; Fig. 6b-1) similar to that
of the oligomers and a length ranging from 150 to
400 nm. No further growth was observed after 3 h.
An additional injection of Aβ42-M led to a further
elongation of the structures and an increase in their
cross-sectional diameter (~4.5 nm; Fig. 6c-1).
When a 4-h-incubation solution containing a
mixture of oligomers and Aβ42-M was added
(Fig. 7), we observed two main structural changes:
(1) an increase in the cross-sectional diameter of the
spherical oligomers (upper histogram in Fig. 7b-1)
and (2) the emergence of elongated oligomers with a
cross-sectional diameter of ~2 nm (lower histogram
in Fig. 7b-1) and a length ranging from 45 to 430 nm.
Predeposited oligomers rarely underwent elongation
(asterisk in the insets)—a finding that is consistent
with the low concentration of Aβ42-M in these
preparations. Figure 7 reveals that the elongated
oligomers originated from the predeposited spherical
ones (circles in the insets).We also attempted to ascertain whether preformed
protofibrils were capable of associating and growing
upon the surfaces of predeposited oligomers, but the
protofibrils did not bind well to the positively charged
surfaces (Fig. 8). However, the spherical oligomers in
these preparations (Fig. 8a and a-1) were observed to
associate and grow upon the surfaces of preexisting
spherical-to-elongated oligomers (Fig. 8b and b-1).
Figure 8b reveals that, 4 h after the injection of a
solution containing protofibrils, the spherical oligo-
mers underwent elongationwithout a change in cross-
sectional diameter. The growth of the oligomers
followed the orientation of the ordered trigonal units
comprising themica surface.37 The oligomers grew to
form elongated oligomers with a length that did not
exceed~300 nm.Forty-fiveminutes after the injection
of freshly purified Aβ42-M into the fluid cell, the cross-
sectional diameter of the observed elongated oligo-
mers (Fig. 8b-1) increased to 4 nm (Fig. 8c-1 and c-2),
which is close to thatmeasured byAFM in air (Fig. 1b).
Figure 8c-1 reveals the beaded, chain-like structure of
the protofibrils. The consecutive series of images in
Fig. 9 depict in real time the structural transition from
elongated oligomers to protofibrils and the corre-
sponding changes in cross-sectional diameter. At
early incubation times, the newly deposited mono-
mers formed beaded structures upon the preexisting
assemblies. These beaded structures gradually
transformed into smooth-contoured structures with a
cross-sectional diameter that was twice as great as
that of the oligomers (see also Fig. S7). These
observations support the hypothesis that Aβ42
Fig. 6. Real-time AFM images illustrating the structural transition from oligomers to protofibrils, together with histograms
depicting changes in the numerical distribution of the cross-sectional diameters of the linear structures (a-1, b-1, and c-1).
(a) Before the addition of fresh Aβ42-M, spherical oligomers and short linear assemblies of these, with a smooth surface
contour and a cross-sectional diameter of ~2.0 nm, were observed. (b) Forty minutes after the addition of fresh Aβ42-M to
the mica substrate, the short linear assemblies of oligomers had undergone elongation at a rate of 9.9±2.64 nm/min; no
further elongation occurred after 3 h. (c) Two hours after a second addition of Aβ42-M, the linear structures had undergone
further elongation, and their cross-sectional diameter had increased from ~2.0 nm to ~4.5 nm. Scale bars represent
250 nm. The Z scale represents 10 nm.
1773Molecular Basis of Amyloid Polymorphismmonomers play an important role in mediating the
association of oligomers and the growth of protofibrils
(Fig. 9b). However, the branching points where two
elongated structures encountered (Figs. 6–8) were
not generated by secondary-nucleation events as
shown in Fig. 1. It needs to be stressed here that,
owing to the constraints imposed by the substrate,17
neither the lateral association of protofibrils nor the
formation of twisted fibrils was observed in the in situ
experiments.Discussion
To understand the role played by Aβ aggregation
in the pathogenesis of Alzheimer's disease, and thus
to be in a position to develop effective strategies for
its treatment, it is necessary to have a clear
conception of the molecular mechanisms underlying
amyloid formation and the contribution of each
intermediate. Although previous studies have
shown that Aβ peptides can self-assemble into
polymorphic fibrillar structures, the mechanisms
underlying this process and the relationship existingbetween the different fibrillar forms of Aβ are poorly
understood. In vitro, the morphology of the final fibrils
and the extent of their heterogeneity (in terms of
diameter, length, and the degree of twisting) depend
not only up on the amino acid sequence but also
upon many other factors, including the absence or
presence of agitation during the process of
aggregation,38,39 protein concentration,14,20 the
physical properties (pH15 and temperature16) and
composition of the incubation medium (nature of the
buffer,15 salt concentration,15,17 and the absence or
presence of a detergent15), the type of seeding
species,13,18,38 and the mode of microscopic
analysis.13,19 Single protein molecules of, for exam-
ple, Aβ,40 amylin,41 insulin,42 or calcitonin,14 are
indeed known to exhibit a broad diversity of
morphologies under the same incubation conditions.
Petkova et al. have suggested that the polymor-
phism of Aβ40 fibrils might be attributable either to
variations in the molecular structure of the protofila-
ments or to differences in their mode of lateral
association that would have no impact on their
molecular structure.38 Others have proposed that
conformational differences at the level of the
Fig. 7. Real-time AFM images
illustrating the structural transition
of oligomers, together with histo-
grams depicting changes in the
numerical distribution of cross-
sectional diameters of the observed
structural entities (a-1 and b-1). (a)
Before the addition of oligomeric
Aβ42, spherical oligomers (asterisk
in inset) and short linear assemblies
of these (circle in inset), with a
smooth surface contour and a
cross-sectional diameter of ~2 nm,
were observed. (b) One hour after
the addition of fresh oligomeric
Aβ42 (to a 4-h-incuation sample),
the cross-sectional diameter of the
spherical oligomers had increased
(upper histogram), and the short
linear structures had undergone
elongation at a rate of 0.75±0.25 nm/min, without a change in cross-sectional diameter (circle in inset and lower
histogram). Scale bars represent 500 nm and 100 nm [inset in (b)]. The Z scale represents 10 nm.
1774 Molecular Basis of Amyloid Polymorphismmonomeric protein39 or in the manner in which the
early oligomers assemble17 prior to protofilament
formation could account for the polymorphic nature
of Aβ fibrils. The importance of improving our
understanding of the molecular and structural basis
of fibrillar heterogeneity has been recently brought
home by indications that the various strains of
disease-inducing prions arise as a result of differ-
ences in fibrillar structure. This finding accords with
observations that fibrils with different morphologies
exhibit distinct properties of resistance to
proteases43 and chemical denaturants44 and of
seeding efficiency.45 In some cases, the fibrils also
differ in molecular structure and in their dye-binding
properties.46
In the present study, we investigated amyloid
formation and the structural properties of Aβ42
species. In particular, we addressed the influence of
the following: (1) the aggregation state of the starting
material (monomers, oligomers, or protofibrils), (2) the
concentration of the monomeric protein at different
stages of amyloid formation, (3) incubation time, and
(4) secondary-nucleation events. Previous TEM
studies have indicated that the type of negative
staining can influence the morphology of Aβ
fibrils.13,14,19 In contrast to TEM, the visualization of
structures by AFM does not require them to be
stained. Hence, we used this methodological tool to
explore the molecular topography of the structural
entities that are generated during amyloid formation
and tomonitor the dynamics of this process in solution
under conditions that approach those pertaining in
vivo.17,21,47–49 Hitherto, most AFM studies relating toAβ have involved the use of Aβ40; Aβ42 has been
employed but rarely.48,50,51 We have taken advan-
tage of the reproducible protocols that have been
developed in our laboratory52 for the preparation of
monomeric, protofibrillar, and fibrillar Aβ42 to address
the aforementioned issues.Molecular basis of the polymorphism of Aβ42
fibrils
Although the precise mechanism governing Aβ42
aggregation in vivo remains uncertain, the data
presented in the present study have afforded a novel
insight into the process and have led us to propose a
mechanistic model for the formation, growth, and
self-assemblage of Aβ42 fibrils in vitro. Our findings
demonstrate that the oligomeric state of the starting
material and the relative concentrations of the
different Aβ42 species (monomers, oligomers, and
protofibrils) have a profound influence on the
polymorphism and the structural heterogeneity of
the resulting fibrils. Using purified and homogeneous
preparations of monomeric Aβ42 (Aβ42-M), we
observed this species to undergo self-assemblage
initially into spherical oligomers and subsequently
into beaded, chain-like protofibrils with different
periodicities (~25 nm or ~40 nm) but the same
cross-sectional diameter (~4 nm). These protofibrils
then gave rise mainly to type-1 and type-2 fibrils.
However, we also observed type-3 and wider fibrils,
which are formed by the lateral association or
stacking of two type-2 fibrils.
Fig. 8. Real-time AFM images (a–c) and the corresponding three-dimensional reconstructions (a-1, b-1, and c-1) of the
structural transition from oligomers to protofibrils, together with histograms depicting changes in the numerical distribution
of cross-sectional diameters of the linear structures (a-2, b-2, and c-2). (a, a-1, and a-2) Before the addition of Aβ42-PF,
spherical oligomers and short linear assemblies of these, with a smooth surface contour and a cross-sectional diameter of
~2 nm, were observed. (b, b-1, and b-2) Four hours after the addition of Aβ42-PF (24-h-incubation sample), the short
linear structures had undergone elongation at a rate of 1.44±0.34 nm/min, without a change in cross-sectional diameter.
(c, c-1, and c-2) Forty-five minutes after the addition of Aβ42-M, the linear structures had undergone further elongation, and
their cross-sectional diameter had increased from ~2.0 nm to 4.0 nm. (c-1) illustrates particularly well the bead-like nature
of a linear assemblage of spherical oligomers. Scale bars represent 500 nm. The Z scale (a–c) represents 10 nm, and that
in (a-1), (b-1), and (c-1) represents 6.5 nm.
1775Molecular Basis of Amyloid PolymorphismIn previous studies, we have demonstrated that, in
the absence of measurable amounts of monomeric
Aβ42, purified protofibrils elongate very slowly and
fail to form mature fibrils.33,34 Upon the addition of
excess monomeric Aβ42, protofibrils undergo rapid
conversion to fibrils. Hence, we assessed the
formation of fibrils from protofibrils in the presence
of different concentrations of Aβ42-M. When fibrillo-
genesis was initiated using a mixture of Aβ42-M and
Aβ42-PF, predominantly mature, type-4 fibrils wereformed. Both the degree and the rate of conversion
of protofibrils to fibrils rose with an increase in the
concentration of Aβ42-M. Under these conditions,
we observed the intermediate subfibrillar structures
that associate to form the protofilaments then two or
three of thicker protofilaments intertwine to form
stable type-4 or type-5 fibrils, respectively. No
secondary-nucleation events were observed upon
the surfaces of either type-4 or type-5 fibrils.
Furthermore, when fresh monomeric Aβ42 was
Fig. 9. (a) Real-time AFM images (right) of the structural transition from an elongated oligomer to a protofibril, together
with graphs tracing the change in cross-sectional diameter of the imaged structure. Twenty-eight minutes after the addition
of Aβ42-M to the elongated oligomer that is imaged at timepoint zero (0 min), monomers had begun to attach to one end of
the linear structure (yellow circles in the scheme of the imaged entity). After 38 min, the sequential addition of new
monomers to the preexisting (aligned) ones had continued. After 46 min, the process of monomer addition had begun also
at the other end of the linear oligomer (white arrow). After 54 min, the process of monomer addition had progressed.
Between 54 min and 61 min, the linear structures bearing the aligned monomer began to undergo a marked increase in
cross-sectional diameter (see the circled regions in the graphs), which denoted their transformation into protofibrils. The
scale bar represents 45 nm. The Z scale represents 5 nm. (b) Model representing the transition from oligomers to
protofibrils during in situ Aβ42 fibrillogenesis.
1776 Molecular Basis of Amyloid Polymorphismadded to solutions containing predominantly proto-
filaments, type-1 fibrils were formed. This finding
suggests that newly added monomers assemble
independently and do not become incorporated into
the protofilaments. Our data indicate that the
polymorphism of Aβ42 fibrils may arise (1) by their
lateral association (yielding type-3 and wider fibrils)
and (2) by the association of different numbers of
protofilaments (yielding fibrils with different cross-
sectional diameters and periodicities, e.g., type-4and type-5). Previous studies have shown that Aβ40
forms polymorphic fibrillar structures and suggested
that Aβ40 polymorphism may be due to the
existence of multiple assembly pathways17 that are
strongly dependent on solution conditions (e.g.,
protein concentration, pH, and growth condition).39
Oligomeric structures of similar dimensions to those
reported here have been observed for Aβ40.53
However, direct comparison of the kinetics and
structural transitions between these different studies
1777Molecular Basis of Amyloid Polymorphismis not possible due to the large differences in the
starting aggregation states of the protein and
experimental conditions.Secondary nucleation is fibril-type specific
Recent studies have indicated that, in addition to
primary nucleation and elongation, the growth and
assemblage of fibrils can occur via secondary
nucleation upon the surfaces of specific, preexisting
fibrils.54–56 Knowles et al. have proposed a model of
biomolecular self-assemblage for insulin, β2-micro-
globulin, and yeast prions that couples primary
nucleation and secondary nucleation leading the
formation of additional nuclei from the end of
preexisting filaments (called fragmentation) with
linear growth.55 Moreover, Andersen et al. have
demonstrated that new fibrils of glucagon could be
formed from preexisting ones by branching.56 In
addition, the kinetic signature of sigmoidal reaction
showing the long lag phase followed by a rapid
growth always indicates the generation of new
aggregates during the aggregation of tau, 25
islet,26,27 and insulin30 fibrils. The nucleation reac-
tion orders extracted from the kinetic curves allow us
to distinguish the fibril fragmentation and surface-
catalyzed nucleation.24
It is important to study the secondary nucleation
because it might also contribute to the proliferation of
fibrils in the brains of patients with Alzheimer's
disease, thereby leading to its progression. Similar to
our observations, several studies have shown that
Aβ40 fibril grows unidirectionally from the end of
preexisting fibrils and the occurrence of secondary
nucleation and fibril branching during fibril formation
Aβ40,15,56–58 IAPP,26 and other amyloid forming
proteins using solution measurements and imaging
techniques (e.g., AFM or total internal reflection
fluorescence microscopy).15,56–58
However, the occurrence of secondary-nucleation
sites on preexisting fibrils has not been hitherto
demonstrated during fibrillogenesis from Aβ42. We
therefore sought to investigate this process and to
elucidate the molecular factors governing its occur-
rence and specificity. Previous studies by Andersen
et al.20,56 and others59–61 demonstrated that parts of
fibril surfaces have the capacity to nucleate fibrilliza-
tion resulting in the branching, growth away or along
the parent fibril. Under conditions that favored the
formation of other fibril varieties (e.g., type-4 and
type-5), no secondary-nucleation events were ob-
served, even after the addition of fresh Aβ42-M
(Fig. 4). On the basis of AFM observations combined
with statistical analysis on fibrils and kinetic data, we
conclude that inherent secondary-nucleation sites
do indeed exist and that they are fibril-type specific.
In the case of Aβ42, only type-2 fibrils appear to be
capable of growing via secondary-nucleation events.We note that kinetic studies have already demon-
strated their ability to incorporate primary and
secondary nucleation pathways into the basic kinetic
equations. However, no explicit attempts were made
to describe a secondary nucleation pathway in Aβ42
fibrillogenesis. Correlating the morphological
changes observed by AFM during aggregation with
the kinetic data combined with the systematic
analysis of fibril height, periodicity, and height
difference from the AFM data allowed us to provide
a framework for the existence of secondary nucle-
ation along fibrils and propose a testable assembly
model for Aβ42 fibrillogenesis. Our findings afford—
for the first time—evidences consistent with the
secondary nucleation model that occurs upon
the surfaces of preexisting fibrils, mainly on those
of the type-2 variety.The concentration of monomeric Aβ42 governs
the assemblage of oligomers and protofibrils
and the structure of the resulting fibrils
Previous studies of our own33,34 and of other
investigators62,63 indicate that the concentration of
monomeric Aβ (Aβ40 and Aβ42) governs the
aggregation, toxicity, and pathology of these pep-
tides. In the present study, we addressed the role of
Aβ42-M in regulating the formation of fibrils at
different stages of the process by means of real-
time in situ AFM. Our results demonstrate that the
presence of monomeric Aβ42 is crucial for the
assemblage of oligomers and protofibrils and for the
growth and formation of fibrils. In the presence of
Aβ42-M, spherical oligomers grew at a rate of 9.9±
2.64 nm/min to form elongated, smooth-contoured
structures with an average length of 150–400 nm.
The average cross-sectional diameter of preformed
oligomers that had been deposited on mica
accorded well with that of dimers formed by
hydrogen bonding between two Aβ42 monomers.22
After their assemblage, the cross-sectional diameter
of these oligomers remained unchanged. Upon the
addition of fresh Aβ42-M, we observed the sequen-
tial deposition of spherical oligomers upon their
surfaces, giving rise eventually to structures with a
cross-sectional diameter (~4 nm) that was twice as
great as that of the original oligomers. The final
structure and cross-sectional diameter of the proto-
fibrils corresponded to those of protofibrils observed
in the ex situ samples (Fig. 1b). These findings
demonstrate that preexisting oligomers serve as
primary-nucleation sites for Aβ42 fibrillogenesis. In
the presence of low concentrations of Aβ42-M, the
spherical oligomers grew at a rate of only 0.75±
0.25 nm/min to form mainly larger spherical struc-
tures. This finding indicates that the presence of
excess monomeric Aβ42 is necessary to mediate
the assemblage of spherical oligomers and the
1778 Molecular Basis of Amyloid Polymorphismformation of protofibrils. Gosal et al. suggested the
bifurcated pathway of β2-microglobulin at which
semiflexible (worm-like) fibrils were formed rapidly
during assembly via a non-nucleated pathway that is
distinct from the formation of relatively rigid long-
straight fibrils.64 However, we could rule out this
possible bifurcated pathway because we observed
that protofibrils (height=3.95±0.64 nm)were formed
by direct association of spherical oligomers and that
these oligomers disappeared upon protofibril or fibril
formation. However, we cannot rule out that other
population the oligomers that form early represent
off-pathway oligomers and re-enter the pathway of
amyloid formation after monomer depletion. Our
observations that monomeric Aβ42 yields predomi-
nantly type-1 and type-2 fibrils, whereas mixtures of
Aβ42-M and Aβ42-PF give rise mainly to type-4 and
type-5 fibrils, likewise demonstrate that the concen-
tration of free monomers is important for the growth
and association of fibrils.
The molecular mechanisms underlying Aβ fibrillo-
genesis and its role in the process of neurodegenera-
tion are unknown. Progress in this field has been
hampered by the heterogeneous size and morphology
of the Aβ aggregates and by our lack to comprehend
the relationship between the different species. The
studies presented provide novel insights into the
mechanism of Aβ42 fibril formation and growth, as
well as into the molecular basis of polymorphism. In
addition, we provide for the first time evidences for the
existence of secondary-nucleation sites on the sur-
faces of Aβ42 fibrils and demonstrate that Aβ42
monomers play a crucial role in determining the
structural properties and heterogeneity of the fibrils
formed. The proposed mechanistic model indicates
that a lowering of the levels of Aβ peptides and a
targeting of their growth and secondary nucleation
represent viable therapeutic options for the inhibition of
amyloid formation and the progression of neurodegen-
eration in Alzheimer's disease and related disorders.Materials and Methods
Preparation of monomeric and protofibrillar forms of
Aβ42
As described in Jan et al., 1 mg of lyophilized Aβ42 (Yale
University, NewHaven, CT, USA) was dissolved in 50 μl of
pure dimethyl sulfoxide (Sigma-Aldrich).52 We then added
800 μl of ultra-pure water and 10 μl of 2 M Tris-base
(pH 7.6) (Sigma-Aldrich) to the mixture, which was
centrifugated at 600g for 4 min at 4 °C. The supernatant
was aspirated and applied to a size-exclusion column
(SEC; Superdex 75, GE Healthcare, Switzerland), which
had been pre-equilibrated with 10 mM Tris–HCl (pH 7.4).
Two Aβ42 fractions—consisting of monomers (Aβ42-M)
and protofibrils (Aβ42-PF)—were separately collected at
different elution times according to their molecular weightcharacteristics. Their absorbances were measured at a
wavelength of 280 nm in an ultraviolet spectrometer
(Varian). The concentration of the Aβ42 species in each
fraction was determined using amolar extinction coefficient
of 1490 M− 1 cm− 1 and adjusted to a final value of 20 μM.
These solutions were used in our fibrillogenesis study.
Preparation of Aβ42 fibrils
The SEC-purified fractions of Aβ42-M and Aβ42-PF and
a mixture of the two species were incubated separately for
1 month at 37 °C without agitation. To monitor the growth
of fibrils, we added a freshly purified fraction of Aβ42-M
(20 μM) to a tube containing the preformed fibrils. The
morphology of the fibrils was monitored at regular time
intervals by TEM and AFM. The kinetics and extent of fibril
formation were assessed using the ThT-binding assay.ThT-binding assay
A 70-μl aliquot of each Aβ42 sample was added to a
tube containing 20 μl of 100 μM ThT and 10 μl of 500 mM
glycine-NaOH (pH 8.5) (Sigma-Aldrich). The resulting
solution (100 μl) was then transferred to a 384-well
fluorescence plate (Nunc), which was scanned with an
Analyst AD fluorometer (Molecular Devices, Switzerland).
Fluorescence was excited at a wavelength of 450 nm, and
its emission measured at one of 485 nm.Sample preparation for ex situ AFM
A substrate of freshly cleaved mica was incubated with a
10-μl drop of 0.05% (v/v) APTES (Fluka) in Milli-Q water for
1 min at ambient temperature. After rinsing with Milli-Q
water, we dried the APTES-modified mica by the passage
of a gentle flow of gaseous nitrogen. At defined time
intervals, a 10-μl aliquot of each Aβ42 sample was applied
to the APTES-modified mica. After an equilibration period
of 10 min, the substrate was rinsed with Milli-Q water and
then dried by the passage of gaseous nitrogen. AFM was
performed in a Nanoscope IIIa (Santa Barbara, CA), which
was operated in the tapping mode under ambient
conditions using a rectangular cantilever of silicon
(Veeco Probes). The resonance frequency of the probe
ranged between 96 and 168 kHz, and the spring constant
was approximately 5 N/m.Sample preparation for in situ AFM
A5-μl drop of a 1-μMsolution of Aβ42-M, which had been
incubated for 4 h, was applied to the substrate of APTES-
modified mica. After an equilibration period of 30 s, the
mica was rinsed with Milli-Q water to remove non-adherent
Aβ42. Once a stable image of oligomeric Aβ42 was
acquired on the substrate, 30 μl of a 3-μM solution of
Aβ42-M, oligomeric Aβ42, or Aβ42-PFwas injected into the
fluid cell. The substrate was continuously monitored for up
to 7 h. When no further growth was observed, 30 μl of a
3-μM solution of Aβ42-M was injected into the fluid cell to
observe the growth of the elongated oligomers and the
formation of protofibrils. AFM was performed in the tapping
1779Molecular Basis of Amyloid Polymorphismmode using a fluid cell that contained 10 mM Tris–HCl
buffer and a triangular cantilever of silicon nitride (Bruker
Probes). The resonance frequency of the probe ranged
between 9 and 10 kHz, and the spring constant was
approximately 0.08 N/m. AFM images were flattened using
the built-in software; background noise, brightness, and
contrast were suitably adjusted. The statistical analysis of
the images was conducted using Nanoscope IIIa software.Acknowledgements
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